What Olympus does

Olympus Corporation (TSE:7733) is a Tokyo-headquartered global medical technology company founded in 1919, focused on endoscopy, surgical energy devices, and minimally invasive procedural platforms. Following the 2021 spinoff of its imaging (OM Digital Solutions) and scientific (Evident) businesses, Olympus is now a pure-play MedTech company organized into customer-focused divisions including Gastrointestinal Solutions and Surgical and Interventional Solutions. It commands approximately 70% of the global gastrointestinal endoscopy market and operates the world's largest installed base of endoscopy systems, supporting more than 49 million colonoscopy procedures annually across hospitals, ambulatory surgery centers, and specialty clinics in roughly 40 countries.

Its product portfolio centers on the EVIS X1 endoscopy system with AI-assisted lesion detection, the POWERSEAL advanced bipolar surgical energy portfolio, the THUNDERBEAT II hybrid energy system, and the Aplio i800 EUS ultrasound system distributed under exclusive arrangement with Canon Medical USA. The company is actively building a robotic GI surgery presence through the EndoRobotics exclusive global distribution agreement, the Swan EndoSurgical joint venture with Revival Healthcare Capital (up to $458M potential), and a minority investment in Neptune Medical. Recent M&A has extended the portfolio beyond GI: the $270 million BioProtect acquisition (closing Q2 2026) adds a biodegradable balloon spacer for prostate cancer radiation therapy, and the January 2024 Taewoong Medical acquisition adds GI stent delivery systems.

Olympus generates revenue primarily through hardware sales of capital endoscopy and surgical energy equipment, supplemented by recurring service contracts, repairs via 100+ global service stations, and consumables tied to the installed base. Go-to-market is enterprise field sales targeting hospital capital expenditure budgets, with increasing emphasis on the ambulatory surgery center segment and AI-driven sales targeting via MedScout and AcuityMD data platforms. The company employs 29,297 people globally and holds approximately 15,000 patents, with active regulatory headwinds including three FDA warning letters and an import ban on certain Japan-manufactured devices that remain unresolved.

Name

Olympus

Legal name

Olympus Corporation

Website

https://olympus.co.jp

Company type

Public

Founded year

1919

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Olympus Corporation is a global medical technology company specializing in endoscopy systems, surgical energy devices, and minimally invasive procedural platforms, serving hospitals, ambulatory surgery centers, and specialty clinics across approximately 40 countries with the world's largest installed endoscopy base.

Ownership category

akta.pro rank

Product category

Medical Endoscopy and Surgical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation) (HLAHADAB)

akta.pro secondary industries

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN), Advanced Endoscopy (ERCP/EUS/Interventional) (HLAKAEAC), Reprocessing & Endoscope Infection Prevention (AERs, Drying/Storage, Leak Testing, Brushes) (HLAHANAJ)

Keywords

• Endoscopy systems
• Surgical energy devices
• Medical imaging equipment
• Robotic-assisted surgery
• Endoscopic ultrasound

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Products (Endoscopy, Treatment Devices, Surgical Energy): Endoscopy systems and treatment devices form the clear majority of Olympus revenue and operating profit. Includes endoscopes, energy devices, and accessories for GI, surgical, and urological procedures.
2. Service and Consumables (Recurring): Recurring service contracts, repairs, and consumables provide income stability from the large installed base of endoscopy systems globally.
3. Life Science Instruments and NDT Equipment: Industrial imaging and non-destructive testing equipment, though no longer a primary revenue driver compared to medical products.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Olympus Corporation designs, manufactures, and sells medical devices and systems centered on gastrointestinal endoscopy, including the EVIS X1 endoscopy platform with AI-assisted lesion detection, the POWERSEAL and THUNDERBEAT surgical energy portfolios, endoscopic ultrasound systems, and treatment devices such as stents and accessories. The company also distributes robotic-assisted endoscopy technology through exclusive partnerships and is expanding into urology and radiation oncology through the BioProtect acquisition, selling primarily to hospitals, health systems, and ambulatory surgery centers globally.

Product overview

Olympus is a global MedTech company offering a comprehensive portfolio of medical devices centered on endoscopy and imaging, with medical products accounting for the clear majority of revenue and operating profit. The core product lineup includes the EVIS X1 endoscopy system with AI-assisted lesion detection, the POWERSEAL advanced bipolar surgical energy portfolio for open and laparoscopic procedures, THUNDERBEAT II hybrid energy systems, and the Aplio i800 EUS ultrasound system developed in partnership with Canon. The company has expanded into robotic GI surgery through the EndoRobotics global distribution partnership (Robopera system) and Swan EndoSurgical joint venture, while the BioProtect Balloon Spacer acquisition extends the portfolio into urology and prostate cancer care. Olympus competes in hospital and clinic capital-expenditure markets across North America, Europe, and Japan, operating through customer-focused divisions including Gastrointestinal Solutions and Surgical and Interventional Solutions.

Differentiator

Problem solved

Functional benefit

Brands

• POWERSEAL: Advanced bipolar surgical energy portfolio including laparoscopic and open surgery sealing/divide devices
• EVIS X1
• Aplio i800 EUS
• THUNDERBEAT II

Products and services

• EVIS X1 Endoscopy System Flagship endoscopy system with AI-assisted lesion detection and advanced imaging technologies (NBI, RDI, LCI) for gastrointestinal diagnostic and therapeutic procedures, sold to hospitals, GI surgery centers, and ambulatory surgery centers.
• Aplio i800 EUS Premium Ultrasound System Endoscopic ultrasound system co-developed with Canon Medical Systems USA for gastroenterology and pulmonary applications, featuring Shear Wave Elastography and Attenuation Imaging for diagnosis of liver, pancreatic, and gastrointestinal diseases.
• POWERSEAL Advanced Bipolar Surgical Energy Portfolio Series of bipolar electrosurgical instruments for laparoscopic and open surgical procedures across general, gynecological, colorectal, bariatric, urological, thoracic, and vascular surgery, including 5mm laparoscopic devices and FDA-cleared Open Extended Jaw Sealer/Divider.
• THUNDERBEAT II Hybrid Energy System Hybrid energy system combining ultrasonic and bipolar energy for surgical tissue cutting and coagulation in gastrointestinal and other surgical procedures.
• Vathin E-SteriScope Single-Use Rhinolaryngoscope Single-use flexible video rhinolaryngoscope for diagnostic use in otorhinolaryngology, reducing cross-contamination risk versus reusable scopes.
• BioProtect Balloon Spacer System Biodegradable balloon implant that creates spacing during radiation therapy to protect healthy tissues in prostate cancer treatment, used in over 11,000 procedures since 2023 commercial launch, now part of Olympus's urology and oncology portfolio.
• EndoRobotics Robopera Robotic-Assisted Endoscopic System Robot-assisted endoscopic system including Robopera console, articulated grippers, scope-mounted traction device, and ESD training simulator, distributed globally by Olympus through an exclusive agreement with EndoRobotics Co., Ltd. of South Korea for therapeutic endoscopy.
• 4K LCD Monitor for Endoscopy 4K resolution monitor designed to enhance visualization during endoscopic diagnosis and treatment procedures, supporting improved clinical decision-making.
• Taewoong Medical Stent Products Advanced stent delivery systems including self-expandable metallic stents and biliary stents acquired through the Taewoong Medical acquisition, expanding Olympus's endotherapy device offerings for gastrointestinal procedures.
• Swan EndoSurgical Robotic Platform Robotic platform for minimally invasive gastrointestinal procedures co-developed through the Swan EndoSurgical joint venture with Revival Healthcare Capital, representing Olympus's most significant robotic GI surgery investment and strategic pillar.

Quantifiable outcome

• 49M+ colonoscopy procedures/year supported globally
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature7 records

Partnerships

Four partnerships are on record, tiered core and minor.

• EndoRobotics Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 4 May 2026Olympus signed an exclusive global distribution agreement with South Korea-based EndoRobotics to distribute robot-assisted endoscopic technologies (Robopera system console, articulated grippers, scope-mounted traction device, and ESD training simulator) as part of Olympus's EndoTherapy portfolio. The U.S. is the initial market target, with additional regional launches subject to regulatory approvals. The collaboration combines Olympus's global commercial infrastructure with EndoRobotics's development capabilities to advance therapeutic endoscopy worldwide.
• Canon Medical Systems USAcoreChannel Partner/ Reseller/ Distributor · 30 April 2026Canon Medical Systems manufactures the Aplio i800 EUS premium ultrasound system; Olympus distributes exclusively in the U.S. for gastroenterology and pulmonary endoscopic use. The system features Shear Wave Elastography and Attenuation Imaging to support diagnosis of liver, pancreatic, and gastrointestinal diseases. This represents a strategic expansion of Olympus's EUS (endoscopic ultrasound) portfolio.
• Healthcare Plastics Recycling CouncilminorStrategic or Co-development Partner · 1 January 2026Olympus participates in the Healthcare Plastics Recycling Council alongside Johnson & Johnson, Stryker, Boston Scientific, and others to develop standardized labeling guidelines for flexible and rigid medical packaging materials to improve recyclability across suppliers and manufacturers.
• Taewoong Medical Co. Ltd.coreStrategic or Co-development Partner · 1 January 2024Olympus acquired Taewoong Medical in January 2024 to strengthen its interventional endoscopy portfolio with advanced stent delivery systems (self-expandable metallic stents). Taewoong specializes in GI stents including biliary stents, expanding Olympus's endotherapy offerings.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Karl Storz SE & Co. KG: Privately held German endoscopy systems manufacturer that is Olympus's most direct global competitor across flexible and rigid endoscopy, visualization, and OR integration. Directly comparable on product category, customer base (hospitals/ASCs), and surgical energy adjacencies.
• Fujifilm Holdings (Healthcare): Fujifilm's endoscopy and medical systems business directly competes with Olympus in GI endoscopy imaging and scopes. Comparable in product mix, geography, and target customer (hospitals and GI clinics).
• Hoya Corporation (Pentax Medical): Hoya's Pentax Medical division manufactures flexible endoscopes and competes head-to-head with Olympus in GI endoscopy systems. Comparable across product line, channel model, and end markets.
• Cook Medical: Privately held medical device manufacturer with strong positions in GI endoscopy accessories, stents, and interventional endoscopy — directly overlapping Olympus's endotherapy portfolio (e.g., Taewoong stents) and customer base.

Broad incumbents

• Boston Scientific Corporation: Large diversified medtech incumbent with significant overlap in endoscopy-adjacent therapeutic devices, GI interventions, and urology. Comparable customer base and capital-sales model, but broader portfolio dilutes direct overlap.
• Stryker Corporation: Diversified medtech incumbent operating across surgical equipment, endoscopy visualization, and surgical robotics (Mako). Comparable in hospital-channel GTM and capital equipment cycles, though broader than GI endoscopy.
• Medtronic plc: Global medtech incumbent with adjacent GI, surgical, and endoscopy-relevant product lines. Comparable in scale, hospital channel, and recurring revenue mix, but not a head-to-head endoscopic scope competitor.
• Johnson & Johnson (MedTech / Ethicon): Through Ethicon and J&J MedTech, competes with Olympus in surgical energy devices and endoscopy adjacencies. Comparable customer base and global hospital footprint, though broader and more diversified.
• Hologic, Inc. Medtech company with diagnostic and surgical franchises adjacent to Olympus's imaging and women's health/oncology exposure. Comparable in hospital channel and recurring revenue model, though limited direct endoscopy overlap.

Emerging players

• Intuitive Surgical, Inc. Dominant robotic surgery platform whose da Vinci system sets the competitive benchmark Olympus's Swan EndoSurgical and EndoRobotics partnerships aim to challenge. Overlaps in minimally invasive GI and soft-tissue procedures and in hospital capital sales motion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Olympus_Corp_JP
• LinkedInlinkedin.com/company/olympus

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries13 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A13 records

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Olympus